/

Società

Al

Non verificato

AliveDx

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaSanitàStart-up

6 comunicati stampa

Guarda tutti i comunicati

03/04/2025

Farmaceutica

Sanità

Economia

Start-up

Biologia

AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray

Fonte

Emittente

1.00

0

10/02/2025

Farmaceutica

Sanità

Economia

Start-up

Biologia

AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Celiac Disease (CD) multiplex microarray

Fonte

Emittente

1.00

0

03/02/2025

Farmaceutica

Sanità

Economia

Start-up

Biologia

AliveDx Expands Autoimmune Menu with IVDR-CE Marked MosaiQ AiPlex® CTDplus Multiplex Assay to Aid in Diagnosing Systemic Autoimmune Rheumatic Diseases and Streamline Laboratory Workflow

Fonte

Emittente

1.00

0

03/09/2024

Farmaceutica

Sanità

Economia

Start-up

AliveDx Receives IVDR-CE Mark for Multiplexed Assay to Accurately Detect Celiac Disease (CD) on the MosaiQ® System

Fonte

Emittente

1.00

0

30/07/2024

Farmaceutica

Information Technology

Telecomunicazioni

Software

Sanità

Economia

Start-up

Biologia

AliveDx Announces Turnkey Solution for Precise, Automated Autoimmune Diagnostics

Fonte

Emittente

1.00

0

29/07/2024

Farmaceutica

Information Technology

Telecomunicazioni

Sanità

Economia

Start-up

Biologia

AliveDx Receives IVDR CE Mark for Groundbreaking Microarray Immunoassay in Allergy Diagnostics

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0